Registration is closed.
Balance between Incentives for Innovation and Achievement of Sustainable Development —Experiences of the Doha Declaration and CBD and their Implications
Workshop Language: English
The Doha Declaration paved the way for developing countries to limit patent protection for medicines, giving them easier access to medicine without negating the treaty obligation of the TRIPS Agreement. Giving an overview of developing countries’ experiences, this workshop explores the appropriate balance between the promotion of innovation on one hand and sustainable development on the other by analysing prior access to medicine and discussions relating to biodiversity. Referring to past events, this workshop may also touch upon the implications of climate change issues. Hiroshi Kato (Faculty of Law, Nihon University) will give an overview of the tension between access to medicine and patent protection, and that between CBD and patent protection. He will explain and analyse examples where compulsory licenses were ordered by the government. In addition, the relevant theoretical and practical framework of the CBD will be reviewed and analysed. Mitsuo Fujii (Director, Intellectual Property, Japan Pharmaceutical Manufacturers Association) will explain the driving factors for innovation and emerging innovation model in the pharmaceutical companies, referring to both general and special features of the industry. In addition, he will give an overview of cases of both philanthropic and business-based cooperation with developing countries. He will also propose an intellectual property system for the pharmaceutical industry. Takeshi Hishinuma (Visiting Research Fellow, UNU-IAS), after briefly explaining the outcomes of past two events relating to the WIPO Green and Public-Private Partnership, will add analyses on the implications of the relationship between climate change and intellectual property. Perspectives on the international community and international norm under the current diplomatic atmosphere may be touched upon as well.
|15:30 - 15:35||Opening Remarks|
Govindan Parayil, UNU Vice-Rector and UNU-IAS Director
|15:35 - 16:00||Mitsuo Fujii, Director, Intellectual Property, Japan Pharmaceutical Manufacturers Association|
|16:00 - 16:25||Hiroshi Kato, Patent Attorney, Aoyama & Partners; Professor, Faculty of Law, Nihon University|
|16:25 - 16:35||Takeshi Hishinuma, Visiting Research Fellow, UNU-IAS|
Video and Audio Podcasts
Mitsuo Fujii (Director, Intellectual Property, Japan Pharmaceutical Manufacturers Association [JPMA])
PhD from the Graduate School of Life Chemistry, Tokyo Institute of Technology (1987); Central Research Laboratry, Yamanouchi Pharmaceutical Co., Ltd. (1987-1995); Patent Department, Yamanouchi Pharmaceutical Co., Ltd. (1995-2005); Intellectual Property, Astellas Pharma Inc. (2005-2012); Visiting Scholar, National Graduate Institute for Policy Studies (2010-2011).
Hiroshi Kato (Patent Attorney, Aoyama & Partners; Professor, Faculty of Law, Nihon University since 2009)
BA (1988), MA (1990) in Pharmacology, the University of Tokyo; PhD in Public Policy, Tohoku University (2008). Patent Examiner, Japan Patent Office (1990-2004, 2007-2008); Harvard University (1997); Associate Professor, National Graduate Institute for Policy Studies (2005-2007). Takeshi Hishinuma (Visiting Research Fellow, UNU-IAS)
Specializes in intellectual property (IP) issues, particularly in the context of international law and cross-border business transactions. Held positions at the World Intellectual Property Organization (WIPO), the United Nations Commission on International Trade Law (UNCITRAL), and the United Nations Industrial Development Organization (UNIDO). BA in Law from the University of Tokyo; LL.Ms from Harvard Law School and the New York University School of Law; Certificat en relations internationales from Institut universitaire de hautes études internationales (HEI) of the University of Geneva.
Registration is free and open to the public. For further information, please contact UNU-IAS at unuias [at]ias.unu.edu or 045-221-2300.